1,3-propanodiol, mínimo 98 %, para síntesis, 500 ml, envase de vidrio

N-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-5,6,7,8-tetrahydronaphthalen-1-amine, 98%, 5mg

1-Methyl-4-piperidone, 99.00%, 25g

(S)-3-((tert-Butoxycarbonyl)amino)-3-(m-tolyl)propanoic acid, 95.0%, 100mg

2-(Methylamino)isoindoline-1,3-dione, 95.0%, 5g

N-(4-(4-Fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide, 95.0%, 25g

tert-Butyl 2-(hydroxymethyl)azetidine-1-carboxylate, 95.0%, 5g

4,4',4'',4'''-((Benzene-1,2,4,5-tetrayltetrakis(methylene))tetrakis(oxy))tetrabenzaldehyde, 98%, 100mg

4-Chloroimidazo[2,1-f][1,2,4]triazine, 95.0%, 1g

2-(Trifluoromethoxy)benzenesulfonamide>98.0%(GC)(T)5g

3-(4-Methylphenyl)aniline, 98%, 1g

Hexaphenyldisiloxane>96.0%(GC)25g

Fmoc-(S)-3-Amino-4-(1-naphthyl)-butyric acid, 97%, 100mg